Studies have shown that the expression of CD39 is increased in pancreatic cancer, rectal cancer primary tumors and metastatic tumors, and that CD39 blockade provides better prognostic value [40,41]. This evidence concerns the gene ENTPD1 and metastatic neoplasm.